Premium
Altered expression of matrix metalloproteinase‐2 correlates with increased vasoactive intestinal peptide in a murine model of asthma
Author(s) -
Samarasinghe Amali Eashani,
Hoselton Scott Alan,
Schuh Jane Marie
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.671.4
Subject(s) - vasoactive intestinal peptide , matrix metalloproteinase , immunohistochemistry , epithelium , medicine , endocrinology , messenger rna , asthma , aspergillus fumigatus , neuropeptide , immunology , biology , pathology , gene , biochemistry , receptor
Vasoactive intestinal peptide (VIP) is a pleuripotent neuropeptide and cytokine that we hypothesize may regulate the production of matrix metalloproteinase (MMP)‐2 in asthma. METHODS: As the first step of this investigation, mice were sensitized and challenged with Aspergillus fumigatus to elicit allergic airways disease. Expression of VIP mRNA was determined with real‐time PCR. Total MMP‐2 expression in serum was determined by enzyme‐inked immunosorbent assay (ELISA), and immunohistochemistry was used to identify the spatial expression of VIP and MMP‐2 in the allergic lungs. RESULTS: The mRNA for VIP was markedly increased 14 days post challenge in comparison to naïve controls. Serum MMP‐2 peaked at day 7, and was most prominent in the columnar epithelium. While naïve animals showed constitutive VIP production in the airway columnar epithelium and smooth muscle surrounding arterioles, experimental animals produced more VIP in these regions as well as the alveolar lining. CONCLUSION: VIP production spatially and temporally correlates with MMP‐2 expression, suggesting its role as a regulator of this important matrix proteinase. Research supported by Grant Number 2P20RR015566 from the National Center for Research Resources (NCRR).